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[infection with the gastric]{.smallcaps} bacterium *Helicobacter pylori* (*H. pylori*) is associated with inflammation of the gastric mucosa that, in some patients, progresses to tissue remodeling involving the development of a hyperproliferative condition and loss of some epithelial cell types, notably parietal cells ([@r7], [@r8], [@r10], [@r11]). These changes may lead eventually to gastric cancer ([@r43], [@r44]). Environmental and bacterial factors are both recognized to influence the progression of these changes with chronic infection. In addition, host factors that influence epithelial responses to infection have been identified including genetic background ([@r18], [@r35]), altered expression, and secretion of hormones, e.g., gastrin ([@r33]), growth factors such as heparin-binding epidermal growth factor (HB-EGF) ([@r55]), cytokines including IL-8 ([@r12]), and extracellular proteases such as matrix metalloproteinase (MMP)-7 ([@r4], [@r13], [@r56]). Although considerable progress has been made in recent years, the interactions between these systems are still poorly understood.

In many different tissues, the responses to infection and injury include induction of members of the urokinase plasminogen activator (uPA) system ([@r2]). The key components of this system are uPA itself, which mediates the conversion of plasminogen to plasmin, its receptor (uPAR), which localizes uPA on the cell surface, and several plasminogen activator inhibitors (PAI-1, -2, and -3). Stimulation of uPA/plasmin is implicated in fibrinolysis, degradation of extracellular matrix, activation of other proteases including multiple MMPs, and modulation of cell-matrix interactions ([@r2], [@r36]). In addition to inhibition of uPA, both PAI-1 and PAI-2 are recognized to have uPA-independent actions. In the case of PAI-1, these are thought, at least in part, to be a consequence of binding to vitronectin ([@r14]). Moreover, although PAI-2 is a secreted protein, its signal sequence is relatively weak and there is a substantial pool of intracellular PAI-2 that is thought to play a role in inhibiting apoptosis ([@r15]); the biology of PAI-3 is not well understood. Until recently the role of this system in gastric physiology and pathophysiology was relatively unknown.

Recently, we reported increased expression of PAI-2 in the gastric epithelium in patients infected with *H. pylori* ([@r54]). Previous studies have contributed to the view that uPA, PAI-1, and uPAR are all associated with an adverse outcome in gastric cancer ([@r21], [@r23], [@r27], [@r40], [@r46]), as well as other tumors ([@r1], [@r48]). However, the roles of these proteins in response to *H. pylori* infection in the normal epithelium are unknown. In the present study, we therefore asked whether there is *H. pylori* stimulation of uPA, uPAR, or PAI-1 in human gastric epithelial cells; we report here that there is and that induction is linked to a proliferative response to infection.

MATERIALS AND METHODS
=====================

Plasmids, drugs.
----------------

PAI-1 antisense oligonucleotides (ASO) and control scrambled oligonucleotides (CSO) were obtained from Biognostik (Gottingham, Germany). Human recombinant uPA, EGF, tissue inhibitor of metalloproteinases (TIMP)-1, and TIMP-3, and GM6001 were obtained from Calbiochem (Nottingham, UK), and uPA activity kit was purchased from Chemicon (Chandlers Ford, UK). 1.94-kb, 4.5-kb, and 2.3-kb fragments of the human uPA, PAI-1 and uPAR promoters, respectively, were generated by PCR of human genomic DNA and cloned into the firefly luciferase reporter construct pXP2 using methods previously reported ([@r52]). Antibodies to uPA, PAI-1, and uPAR were obtained from American Diagnostica (Stamford, CT), antibody to the EGF receptor was purchased from Oncogene (Cambridge, MA), and antibodies to TGF-α, amphiregulin, and HB-EGF were obtained from R&D Systems (Abingdon, UK). uPAR and control siRNA was obtained from Ambion (Austin, TX). Other chemicals were obtained from Sigma (Poole, Dorset, UK).

Patients.
---------

Six endoscopic pinch biopsies of gastric corpus and antrum were obtained from patients referred with dyspepsia (*n* = 33, 18 men, mean age 54.2 ± 1.7 yr) and with *H. pylori* infection confirmed by serology, antral urease test (Prontodry; Med. Inst. Solothurn, Switzerland), and antral and corpus histology; in all cases, histology indicated superficial gastritis but not gastric atrophy or intestinal metaplasia. Patients were excluded if there was a previous history of neoplastic disease, present history of peptic ulcer, or elevated plasma gastrin concentrations (\>30 pM). Dyspeptic patients (*n* = 90, 46 men, mean age 53.9 ± 1.3 yr) with normal fasting plasma gastrin concentrations (\<30 pM), negative *H. pylori* status by serology, antral urease test, and antral and corpus histology were used as controls. The study was approved by the Ethics Committee of the Royal Liverpool and Broadgreen University Hospitals NHS Trust. All patients gave written, informed consent.

Real-time PCR.
--------------

RNA from human gastric biopsies was extracted in Trizol (Invitrogen, Paisley, UK) and DNase treated (Promega, Southampton, UK), and 5 μg were reverse transcribed with avian myeloblastosis virus reverse transcriptase (Promega) and random hexamers (Promega). Real-time PCR was carried out using TaqMan probe/primer sets specific for human uPA (forward primer 5′-ggaaaacctcatcctacacaagga; reverse primer 5′-cggatcttcagcaaggcaat; probe 5′-ctgacacgcttgctcaccacaacga), PAI-1 (forward primer 5′-ggctgacttcacgagtctttcag; reverse primer 5′-cgttcacctcgatcttcactttc; probe 5′-aagagcctctccacgtcgcgca), uPAR (forward primer 5′-cgaggttgtgtgtgggttagac; reverse primer 5′-ggcttcgggaataggtgaca; probe 5′-tgcaaccagggcaactctggcc), PAI-3 (forward primer 5′-tctgtgaccttatgctccacactaa; reverse primer 5′-gcatggtggctgttctttgtt; probe 5′-tctggcagagcctccgtttcctca), and an 18S rRNA control kit (Eurogentec, Southampton, UK). Reactions were performed in an Applied Biosystems (Warrington, UK) PrismTM7700 sequence detection system and quantified using a standard curve. uPA, uPAR, PAI-1, and PAI-3 mRNA abundances were determined relative to 18S in the same sample.

Gastrin radioimmunoassay.
-------------------------

Plasma samples were assayed for total amidated gastrin concentrations by radioimmunoassay using antibody L2 (which reacts with G17 and G34 but not progastrin or Gly-gastrins) as previously described ([@r17]).

Immunohistochemistry.
---------------------

Formalin-fixed, paraffin-embedded tissue sections were processed for immunohistochemical detection of uPA, PAI-1, and uPAR after antigen recovery as previously described ([@r53]).

Cultured human gastric gland cells.
-----------------------------------

Adherent human gastric glands were prepared using the method previously described ([@r56]). Glands were cultured in DMEM/Hams F12 supplemented with 10% FBS and 1% antibiotic-antimycotic solution (Sigma) at 37°C in 5% CO~2~-95% O~2~.

Knockdown of PAI-1 and uPA activity assays.
-------------------------------------------

Human gastric glands were cultured as monolayers and treated with 2 μM PAI-1 ASO sodium salt or the corresponding negative control oligonucleotide (CSO) sodium salt (Biognostik) for 72 h as previously described ([@r37]). Knockdown of PAI-1 was verified by immunocytochemistry. Cells were infected with *H. pylori* strain 60190 \[American Type Culture Center (ATCC)\] for 16 h as described earlier ([@r49]). uPA activity assay was performed from both media and cell extracts according the manufacturer\'s instruction and absorption measured at 340 nm.

Transient transfection and bacterial infection of primary human gland cultures.
-------------------------------------------------------------------------------

Primary human gastric glands cultured for 48 h on 12-well plates were transfected with 2 μg firefly luciferase reporter construct per well together with a constitutively active *Renilla* luciferase reporter, phRL-SV40 (5 ng per well, Promega), using CombiMag (Oz Biosciences, Marseille, France) as previously described ([@r49]). Cells were infected with *H. pylori* strain 60190 (ATCC) and its isogenic mutants at a multiplicity of infection (MOI) of 1:150 for 16 h as described previously ([@r3], [@r54]). Luciferase activity was measured by dual luciferase assay (Promega) in a Lumat LB9507 luminometer (Berthold, Redbourne, UK). Results are presented as fold increase over unstimulated control, so a value of 1.0 signifies no change in luciferase activity.

Cellular targeting of the members of the uPA system in primary human adherent glands.
-------------------------------------------------------------------------------------

To study cellular targeting of uPA, uPAR, and PAI-1-luciferase (luc) expression, transfected primary human gastric glands were double immunostained with goat anti-luciferase antibody (Rockland Immunochemicals, Gilbertsville, PA) together with one of the following: rabbit anti-pepsinogen (gift f;rom Mike Samloff, Center for Ulcer Research, Los Angeles, CA), rabbit anti-H^+^/K^+^ATPase (Calbiochem), rabbit anti-vesicular monoamine transporter 2 ([@r22]), mouse anti-trefoil factor-1 (TFF-1; Dako, Glostrup, Denmark), and mouse anti-TFF-2 (NovoCastra, Newcastle-upon-Tyne, UK) antibodies with appropriate FITC or Texas red-conjugated secondary antibodies (Jackson Immunoresearch, Soham, UK), using Vectashield mounting medium with DAPI (Vector Laboratories, Peterborough, UK) to counterstain nuclei. Slides were examined using a Zeiss Axioplan-2 microscope (Zeiss Vision, Welwyn Garden City, UK) and images captured using a JVC-3 charge-coupled device camera and KS300 software combined with a deconvolution software (Imaging Associates, Bicester, UK). Ten fields from each of three patients were counted; results are expressed as a percentage of total cell number as reported earlier ([@r49], [@r54]).

BrdU labeling.
--------------

Primary gastric glands from *H. pylori*-negative and -positive patients were plated on cover slips in 12-well plates and cultured for 48 h. Glands were then serum starved for 24 h before addition of bromodeoxyuridine (BrdU) (3 ng/ml) with uPA (500 ng/ml) or *H. pylori* (MOI 1:150) and further incubated for 24 h at 37°C. Control scrambled and PAI-1 antisense oligonucleotides were present for 72 h as described above. Control or siRNA to uPAR were transfected using SilenceMag (Oz Biosciences) as previously described and cells incubated for a further 48 h ([@r37]). BrdU was detected with FITC-conjugated fast immune anti-BrdU/DNase (Becton Dickinson, Oxford, UK) using Vectashield mounting medium with DAPI (Vector Laboratories) to counterstain nuclei. Glands were counterstained with vimentin (RDI, Flanders, NJ) and cells with colocalized BrdU and vimentin-positive staining (myofibroblasts) were excluded. BrdU-positive cells were expressed as a percentage of total cell number as previously described ([@r37]).

Statistics.
-----------

Results are presented as means ± SE; comparisons were made using ANOVA or Student *t*-tests where appropriate and were considered significant at *P* \< 0.05.

RESULTS
=======

Increased expression of uPA, uPAR, and PAI-1 in human gastric corpus with H. pylori infection.
----------------------------------------------------------------------------------------------

The results from real-time PCR indicated that uPA, uPAR, and PAI-1 mRNA abundances were significantly increased in human gastric corpus in patients infected with *H. pylori* ([Fig. 1*A*](#f1){ref-type="fig"}). These changes appear to be specific in that there was no significant difference in the abundance of PAI-3 mRNA in gastric corpus, and neither was there a significant difference in the abundance of uPA, uPAR, or PAI-1 in the antrum of individuals infected with *H. pylori* compared with controls ([Fig. 1*B*](#f1){ref-type="fig"}). Plasma gastrin concentrations in the patients infected with *H. pylori* used in this study (21.5 ± 1.6 pM) were within the normal range and were not significantly different from the control group (20.7 ± 1.7 pM), so the differences are not attributable to raised plasma gastrin. Immunohistochemical studies indicated that there was increased PAI-1, uPAR, and uPA in epithelial cells in *H. pylori*-positive subjects, including parietal cells. However, in the case of uPA and uPAR, there was also abundant expression in subepithelial cells with *H. pylori* infection ([Fig. 1](#f1){ref-type="fig"}, *C* and *D*).

H. pylori increases uPA-, uPAR- and PAI-1-promoter/luciferase-reporter expression in primary cultured human gastric glands by distinct mechanisms.
--------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether *H. pylori* directly stimulated transcription of PAI-1, uPAR, and uPA in human gastric epithelial cells, we transfected cultured gastric glands with constructs of PAI-1, uPAR, and uPA promoters coupled to a luciferase reporter (i.e., PAI-1-luc, uPAR-luc, and uPA-luc). In untransfected cells, there was expression of wild-type uPA, uPAR, and PAI-1 in subsets of parietal cells (identified by H^+^/K^+^ATPase staining), chief cells (identified by pepsinogen staining), enhanced chemiluminescence (ECL) cells (identified by chromogranin staining), and mucus cells (identified by TFF-1 staining) ([Fig. 2](#f2){ref-type="fig"}, *A*--*E*). Generally, around 25--30% of parietal, chief, or ECL cells expressed uPA, uPAR, or PAI-1; however, PAI-1 was expressed in a relatively high proportion of ECL cells, and uPA was expressed in less than 10% of chief cells ([Fig. 2*E*](#f2){ref-type="fig"}). uPA, uPAR, or PAI-1 were expressed in less than 15% of mucus cells ([Fig. 2*E*](#f2){ref-type="fig"}). In cells transfected with luciferase promoter-reporter vectors, dual labeling immunofluorescence using antibodies to luciferase and to markers of parietal and ECL cells indicated that expression of the constructs was predominantly targeted to these cells. In addition, however, there was some expression of uPA-luc in chief cells and relatively low expression of uPAR-luc in either chief or surface mucus cells ([Fig. 3](#f3){ref-type="fig"}, *A*--*D*). However, the promoter sequences used in these vectors were not able to direct detectable expression of PAI-1-luc in chief cells or of PAI-1 or uPA-luc in mucus cells indicated by TFF-1 immunoreactivity, or of PAI-1-, uPA- or uPAR-luc in mucus neck cells indicated by TFF-2 expression. Importantly, expression of each luciferase vector was increased in response to *H. pylori* ([Fig. 4](#f4){ref-type="fig"}, *A*--*C*).

To determine whether recognized major virulence factors of *H. pylori* were responsible for stimulation of uPA, uPAR, and PAI-1, isogenic mutants were studied in which the virulence genes *cagA*, *cagE*, and *vacA* were disrupted. Disruption of these virulence factors had no effect on *H. pylori*-stimulated PAI-1 or uPAR expression, but disruption of *cagE* virtually abolished the stimulatory effect of *H. pylori* on the uPA-luc construct ([Fig. 4](#f4){ref-type="fig"}, *A*--*C*), indicating that *H. pylori* acts through separate mechanisms to stimulate PAI-1, uPA, and uPAR.

H. pylori increases uPA activity in cultured human gastric glands, which is enhanced by PAI-1 knockdown.
--------------------------------------------------------------------------------------------------------

Since both uPA and its inhibitor PAI-1 were increased by *H. pylori*, we asked whether there were changes in uPA enzyme activity. Infection of cultured gastric glands with *H. pylori* increased both cell surface-bound and soluble uPA activity ([Fig. 5](#f5){ref-type="fig"}). We then examined the consequences of PAI-1 knockdown. Immunohistochemistry confirmed that PAI-1 antisense oligonucleotide treatment significantly decreased the total number of cells in cultured gastric glands expressing endogenous PAI-1 (CSO, 10.0 ± 0.3% vs. ASO, 3.8 ± 0.2%). Moreover, PAI-1 knockdown ([Fig. 5](#f5){ref-type="fig"}, *A* and *B*) increased both cell surface-bound and soluble uPA activity although the increase was more marked for the latter than the former.

H. pylori acts via uPA to increase epithelial cell proliferation, and PAI-1 knockdown enhances this response.
-------------------------------------------------------------------------------------------------------------

Previous work has linked proliferative responses to *H. pylori* with activation of the EGF receptor, including stimulation of the ligand HB-EGF and its liberation by proteolysis ([@r29], [@r55]). In primary human gastric glands, we showed that *H. pylori* increased BrdU incorporation and that the response was further enhanced by PAI-1 knockdown ([Fig. 6*A*](#f6){ref-type="fig"}). Consistent with the idea that PAI-1 inhibited uPA in this system, we then showed that uPA itself increased BrdU incorporation, and the response was again further enhanced by PAI-1 knockdown ([Fig. 6](#f6){ref-type="fig"}, *B* and *C*).

Treatment of cells with a neutralizing antibody to uPA inhibited the proliferative effect of *H. pylori*, suggesting a role for endogenous uPA in this response ([Fig. 7*A*](#f7){ref-type="fig"}). A role for uPAR in the response was indicated by the observation that knockdown of uPAR with siRNA significantly inhibited *H. pylori*-induced proliferation ([Fig. 7*A*](#f7){ref-type="fig"}). Immunohistochemistry confirmed that siRNA treatment significantly decreased the number of uPAR-expressing cells in cultured gastric glands (control, 9.1 ± 0.5% of positive cells; uPAR knockdown, 3.0 ± 0.4%), whereas PAI-1 expression was not altered (8.4 ± 0.5% vs. 8.8 ± 0.4%). Consistent with these observations, the increased BrdU incorporation in response to exogenous uPA was also decreased by uPAR knockdown ([Fig. 7*B*](#f7){ref-type="fig"}). The specificity of the latter effect is indicated by the fact that there was no decrease in BrdU incorporation after uPAR knockdown in response to an exogenous EGF receptor (EGF-R) ligand (EGF, 50 ng/ml) compared with control (EGF alone, 2.14 ± 0.05-fold increase in BrdU incorporation over control; EGF and uPAR knockdown, 2.36 ± 0.03-fold).

uPA increases epithelial cell proliferation via metalloproteinase release of HB-EGF.
------------------------------------------------------------------------------------

Since there was increased BrdU incorporation in response to exogenous EGF, we asked whether the proliferative response to uPA was linked to activation of the EGF pathway. Neutralizing antibody against EGF-R significantly reduced BrdU incorporation induced by uPA, and so too did the EGF-R tyrosine kinase inhibitor, AG1478 ([Fig. 8*A*](#f8){ref-type="fig"}). Moreover, neutralizing antibody to HB-EGF inhibited BrdU incorporation in response to uPA ([Fig. 8*B*](#f8){ref-type="fig"}), and, in agreement with the idea that HB-EGF mediated responses to uPA, the mutant diphtheria toxin CRM197 also reduced uPA-mediated BrdU incorporation ([Fig. 8*B*](#f8){ref-type="fig"}). Interestingly, however, responses to uPA were not influenced by neutralization of other EGF-R ligands such as amphiregulin and TGF-α that are known to be expressed in gastric mucosa (uPA, 1.90 ± 0.12-fold increase over control; uPA and amphiregulin immunoneutralization, 1.74 ± 0.15-fold over control; uPA and TGF-α immunoneutralization, 2.10 ± 0.15-fold over control). Since it is known that HB-EGF is released by metalloproteinases ([@r47]), we examined the effect of a broad spectrum inhibitor, GM6001, and two tissue inhibitors of MMPs (TIMP-1 and TIMP-3) on proliferative response to uPA. At a concentration of 100 nM, TIMP-1 inhibited BrdU incorporation by 21 ± 5% and TIMP-3 inhibited by 69 ± 10% (*P* \< 0.05), whereas GM6001 inhibited uPA responses by 70 ± 12% (*P* \< 0.05).

DISCUSSION
==========

The present data show that *H. pylori* infection of the human gastric corpus is associated with increased expression of uPA, its receptor uPAR, and its inhibitor PAI-1. It seems probable that separate mechanisms are associated with increased expression of uPA, uPAR, and PAI-1. Thus within the epithelium, both parietal and ECL cells have the capacity to increase uPA, uPAR, and PAI-1 expression in response to *H. pylori*, whereas chief cells can also express uPA, and mucus cells may express uPAR. Moreover, the CagE virulence factor is required for uPA responses to *H. pylori* but not PAI-1 or uPAR. A role for uPA and uPAR in *H. pylori*-stimulated cell proliferation was identified through mechanisms that required HB-EGF and EGF-R activation and were at least partly held in check by PAI-1. The data implicate activation of uPA in the preneoplastic hyperproliferative condition that is associated with *H. pylori* infection. Control of uPA activity may therefore present a new target in arresting *H. pylori*-stimulated progression to cancer.

Previous work has established that uPA, uPAR, and PAI-1 are increased in gastric cancer and in chronic atrophic gastritis ([@r6], [@r19], [@r21], [@r23], [@r27], [@r28], [@r40], [@r46]); moreover, increased expression in cancer is associated with an adverse outcome. There is expression of uPA, uPAR, and PAI-1 in both stromal and tumor cells, and it is generally thought that the expression of these proteins is associated with progression of the disease through increased cell invasion, metastasis, and angiogenesis. In the case of uPA, binding to uPAR generates a focal point of proteolytic activity that facilitates cell invasion ([@r1]). In addition to inhibition of uPA through accelerated internalization of the uPA/uPAR complex, PAI-1 also exhibits uPA-independent actions. Specifically, by binding vitronectin it increases cell dissociation from extracellular matrix and accelerates invasion ([@r14]). It has been suggested that the latter effects account for the association of increased PAI-1 in gastric and other cancers with adverse outcomes, which is sometimes referred to as "paradoxical" given that uPA is also associated with disease progression. In spite of the work on uPA and PAI-1 in gastric cancer, little attention has been given to how this system responds to *H. pylori* infection and how it might be implicated in the tissue remodeling that characterizes the preneoplastic condition.

We previously showed that PAI-2 was increased in gastric epithelial cells in response to *H. pylori* via activation of NF-κB ([@r54]). A pool of PAI-2 is retained within cells and is associated with inhibition of apoptosis, whereas some is secreted and has been shown to be involved in inhibition of invasion of a cancer cell line ([@r54]). The present data now make it clear that infection with *H. pylori* also induces the main members of the system, uPA, uPAR, and PAI-1 in primary, untransformed, gastric epithelial cells; there was no evidence that a third inhibitor, PAI-3, was changed with *H. pylori* infection, and we did not study this further. Previous work using microarrays to identify *H. pylori*-regulated genes demonstrated increased uPA in gastric cancer cell lines ([@r32]), and there has been work using gastric cancer cell lines that indicates *H. pylori* stimulation of uPA, uPAR, and PAI-1 expression ([@r24], [@r30], [@r31]). However, given the nature of cancer cell lines, it remained uncertain how these observations related to expression of members of the uPA system in primary gastric epithelial cells. Our data show that with infection there is the capacity to increase uPA, uPAR, and PAI-1 expression in two cell types associated with the gastric corpus, namely the acid-secreting parietal cell and the histamine-releasing enterochromaffin-like cell; the restriction of both cell types to the gastric corpus is consistent with the observation that there was no difference in expression of uPA, uPAR, and PAI-1 in the antral region of the stomach (where these cell types are absent). In contrast, PAI-2 is prominently expressed in mucin- and pepsinogen-expressing cells and is only occasionally found in parietal or ECL cells ([@r54]); it is also increased in the antrum in *H. pylori*-positive patients (S. Kenny and A. Varro, unpublished observations). Interestingly, only subsets of the major differentiated gastric epithelial cell types expressed uPA, uPAR, or PAI-1; the basis of this requires further work because the different subsets might, for example, vary in terms of age. It is clear that promoters of the length we used in the luciferase reporter vectors do not precisely mimic the patterns of expression of the wild-type gene, indicating that information outside these sequences is required for faithful cell-restricted expression. Even so, at a qualitative level the general patterns of expression of the wild-type proteins and the promoter-reporter vectors were similar. Importantly, the increased abundance of uPA transcripts in response to *H. pylori* was associated with increased enzyme activity in normal gastric epithelial cells that was enhanced still further by blocking PAI-1 expression compatible with a dynamic equilibrium between enzyme and its inhibitor, and with the idea that the changes in transcript abundance were functionally relevant.

*H. pylori* increases plasma gastrin concentrations, and parietal and ECL cells express the CCK-2 receptor at which gastrin acts ([@r16], [@r33]). However, increased abundance of uPA, uPAR, and PAI-1 transcripts was found in patients infected with *H. pylori* with plasma gastrin concentrations in the normal range, and *H. pylori* stimulation of promoter-reporter constructs occurred in epithelial cells in vitro (in the absence of gastrin) so that the effects of *H. pylori* are not secondary to increased gastrin. Although stimulation of uPAR and PAI-1 was independent of the pathogenicity island, we found that a *cagE* isogenic mutant was defective in uPA induction. Disruption of *cagE* means that *H. pylori* cannot make a functional type IV secretory apparatus. This has two effects: first, it blocks Nod1-NF-κB signaling, and second, it blocks delivery of CagA into epithelial cells and the signaling consequent on this. Since disruption of *cagA* had no effect on uPA induction, it is likely that the deficit seen in the *cagE* mutant is due to lack of stimulation of Nod1-NF-κB. This is compatible with the already described role of NF-κB in regulation of uPA transcription ([@r20], [@r28], [@r38], [@r42]). It is worth noting that, in MKN-45 and KATO III cell lines, *H. pylori* stimulation of uPA expression was reported to be abolished by mutation of CagA ([@r24]); differences between cancer cell lines and primary, untransformed, cells used in the present study may well account for this difference.

The data link *H. pylori* induction of uPA to one of the key characteristics of preneoplastic, *H. pylori*-infected epithelium, namely increased cell proliferation. Previous work has shown that *H. pylori* stimulates proliferation and that this includes transactivation of the EGF receptor and stimulation of HB-EGF cleavage ([@r29], [@r45], [@r55]). We demonstrate that the proliferative response of normal human gastric epithelial cells to uPA is mediated by EGF-R. It is possible that there are interactions between ligand-bound uPAR and EGF-R that result in proliferation ([@r25]). However, the cells expressing uPAR in gastric glands (mainly parietal and ECL cells) are distinct from the proliferating cells, and, instead, the data suggest that uPA stimulates proliferation via the release of an EGF-R ligand, HB-EGF. This system is therefore distinct from prostatic DU-145 cells in which uPA-stimulated invasion is mediated by HB-EGF in an autocrine mechanism ([@r9]). Other ligands of EGF-R produced in the gastric epithelium include amphiregulin and TGF-α; however, in contrast to HB-EGF, immunoneutralization of amphiregulin and TGF-α did not inhibit the proliferative responses to uPA. It is known that HB-EGF is cleaved from its cell-bound precursor via proteases that include TNF-α-converting enzyme (ADAM-17) ([@r50]), MMP-3 and MMP-7 ([@r51], [@r57]), and matrilysin ([@r41]). There is also a considerable body of evidence indicating that in different systems there are cascades of proteolytic activation involving uPA, plasmin, and MMPs ([@r34], [@r39]). The data show GM6001, TIMP-1, and TIMP-3 inhibit the action of uPA, consistent with a role for metalloproteinases downstream of uPA although the precise sequence of events by which uPA activates HB-EGF remains to be determined. In this context, it is worth noting, however, that, although uPA activates MMPs and MMPs are known to be increased with *H. pylori* infection, the localization of MMPs in the gastrointestinal mucosa is for the most part subepithelial. Within the normal gastric epithelium, MMP-7 is the predominant representative of this group, and we have already shown that this does not stimulate proliferation in cultured gastric glands ([@r37]).

The well-established association of uPA with pericellular proteolysis in tissue damage and repair raises the prospect that induction of the system in *H. pylori* infection is part of a host response mechanism relevant to the tissue remodeling characteristic of this infection. Previous work has established a variety of different ways that bacteria interact with the uPA system ([@r5]). In the case of *H. pylori,* two plasminogen-binding proteins have been identified that are proposed to coat the organism, and, with the subsequent activation of bound plasminogen to plasmin, these proteins are thought to increase virulence ([@r26]). The present data suggest a further role for this system in stimulation of cell proliferation. With prolonged infection, we suggest that the increased proliferation favors the acquisition of mutations leading to cancer. The present data therefore raise the possibility that inhibition of uPA might be therapeutically useful in those patients at risk of progression from gastric atrophy to cancer.
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![Increased gastric urokinase plasminogen activator (uPA), uPA receptor (uPAR) and plasminogen activator inhibitor (PAI)-1, but not PAI-3, expression in patients infected with *Helicobacter pylori* (*H. pylori*). *A*: real-time PCR normalized to 18S shows elevated uPA, uPAR, and PAI-1 mRNA expression in the gastric corpus in patients with *H. pylori* (*H*. *p*.) infection compared with uninfected individuals (*n* = 13--14, \**P* \< 0.05, ANOVA). *B*: there was no increase in the antrum in uPA, uPAR, or PAI-1 mRNA abundance in patients with *H. pylori* infection compared with controls (*n* = 11--20). *C*: representative examples of low uPA, uPAR, and PAI-1 staining of serial sections of gastric corpus from an uninfected patient compared with a patient infected with *H. pylori* (*D*); control section: first antibody omitted. Black arrows, staining of epithelial cells; yellow arrows, stromal cells.](zh30080851690001){#f1}

![Expression of uPA, uPAR, and PAI-1 in human cultured gastric glands. *A*: controls where primary antibody was omitted (*left*, DAPI staining of nuclei; *middle*, Texas red-labeled donkey anti-rabbit IgG; *right*, FITC-labeled donkey anti-mouse IgG). *B*: example of expression of uPAR (green, *left*) in a pepsinogen-positive cell (chief cell, red, *middle*; merged image, *right*). *C*: example of expression of PAI-1 (green, *left*) in a chromogranin-positive cell, \[enhanced chemiluminescence (ECL) cell, red, *middle*; merged image, *right*\]. *D*: expression of PAI-1 (green, *left*) in a H^+^/K^+^ ATPase-positive cell (parietal cell, red, *middle*; merged image, *right*). *E*: percentage (%) of H^+^/K^+^ATPase-, pepsinogen-, chromogranin-, and trefoil peptide (TFF)-1-positive cells expressing PAI-1, uPAR, or uPA (*n* = 3). Note that \<3.0% of TFF-2-expressing cells expressed uPA, uPAR, or PAI-1.](zh30080851690002){#f2}

![uPA, uPAR, and PAI-1 promoter-reporter constructs target expression to specific cell types in human gastric glands. 1.94 kb of uPA promoter, 2.3 kb of uPAR promoter, and 4.5 kb of PAI-1 promoter coupled to a luciferase reporter were transfected into primary human gastric epithelial cells. *A*: expression of PAI-1-luc (green, *left*) in a H^+^/K^+^ ATPase-positive cell (parietal cell, red, *middle*; merged image, *right*). *B*: expression of PAI-luc (green, *left*) in a vesicular monoamine transporter (VMAT)-2-positive cell, (ECL cell, red, *middle*; merged image, *right*). *C*: expression of uPA-luc (green, *left*) in a pepsinogen-positive cell (chief cell, red, *middle*; merged image, *right*). *D*: percentage (%) of PAI-1, uPAR, and uPA luciferase-positive cells expressing H^+^/K^+^ATPase, VMAT-2, or pepsinogen (*n* = 3). Note that \<1.0% of uPA- or PAI-1-luc-expressing cells also expressed TFF-1 and that \<1.0% of cells expressing all 3 constructs also expressed TFF-2.](zh30080851690003){#f3}

![*H. pylori* stimulates uPA, but not uPAR, or PAI-luc through a CagE-dependent mechanism. *A*: *H*. *pylori* \[16 h, multiplicity of infection (MOI) 1:150\] stimulates expression of uPA-luc that is abolished by deletion of the *cagE* but not *cagA* and *vacA* virulence factors. *B* and *C*: *H*. *pylori* also stimulates expression of PAI-luc and uPAR-luc, respectively, but this is not decreased by deletion of the *cagE*, *cagA*, or *vacA* virulence factors; *n* = 3--15, *P* \< 0.05. (\*control vs. wild-type *H. pylori*; \*\*wild-type *H. pylori* vs. *cagE*-null mutant). wt, wild-type.](zh30080851690004){#f4}

![*H. pylori* increases both cell surface-bound and soluble uPA activity, and PAI-1 knockdown increases activity still further. *A*: cell surface-bound uPA activity after *H. pylori* infection with or without PAI-1 antisense oligonucleotide (PAI-1-ASO, 2 μM) treatment expressed as % of control. *B*: soluble uPA activity after *H. pylori* infection with or without PAI-1-ASO treatment expressed as % of control. In control cells, the cell surface uPA amounted to 48 ± 7% of soluble activity; *n* = 5--13, *P* \< 0.05, ANOVA (\*control vs. *H. pylori*; \*\**H. pylori* alone vs. *H. pylori* with PAI-1 knockdown).](zh30080851690005){#f5}

![Increased gastric epithelial cell proliferation in response to *H. pylori* and uPA. *A*: *H. pylori* stimulated bromodeoxyuridine (BrdU) incorporation of human primary gastric epithelial cells, and this was enhanced by PAI-1 knockdown. *B*: addition of uPA (500 ng/ml) mimicked the stimulatory effect of *H. pylori* on BrdU incorporation, and this was also enhanced by PAI-1 knockdown. *C*: representative examples of BrdU-labeled cells (*right*, arrows) in control (*top*) and uPA-treated glands; DAPI staining of all nuclei shown on *left*; *n* = 4, *P* \< 0.05, ANOVA (\*control vs. *H. pylori* or uPA; \*\**H. pylori* or uPA along compared with PAI-1). CSO, control scrambled oligonucleotides.](zh30080851690006){#f6}

![Increased gastric epithelial cell proliferation in response to *H. pylori* is mediated by uPA. *A*: *H. pylori-*stimulated BrdU incorporation of human primary gastric epithelial cells was inhibited by treatment with neutralizing uPA antibody or knockdown of uPAR with siRNA (60 nM) *B*: uPA (500 ng/ml)-stimulated BrdU incorporation was also inhibited by uPAR knockdown; *n* = 3, \**P* \< 0.05, ANOVA. Ab, antibody.](zh30080851690007){#f7}

![uPA acts through heparin-binding EGF (HB-EGF) to stimulate epithelial cell proliferation. *A*: uPA (500 ng/ml)-stimulated BrdU incorporation was inhibited by neutralizing Ab to the EGF receptor (EGF-R) (2 μg/ml) and by receptor tyrosine kinase inhibitor (Inh) AG1478 (2 ng/ml). *B*: uPA-stimulated BrdU incorporation was also inhibited by neutralizing Ab to HB-EGF (5 μg/ml) and by the mutant diphtheria toxin CRM197 (5 μg/ml); *n* = 3--4, \**P* \< 0.05, ANOVA.](zh30080851690008){#f8}

[^1]: Address for reprint requests and other correspondence: A. Varro, Physiological Laboratory, School of Biomedical Sciences, Univ. of Liverpool, Crown St., Liverpool L69 3BX, UK (e-mail: <avarro@liverpool.ac.uk>)
